ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2021 and some content may be unavailable. To unlock all content for 2021, please visit the archives.

Abstract: PO1601

Serological Activity in Pure Membranous Lupus Nephritis in a Predominantly Black Population

Session Information

Category: Glomerular Diseases

  • 1203 Glomerular Diseases: Clinical, Outcomes, and Trials

Authors

  • Roberts, Levard G., Emory University, Atlanta, Georgia, United States
  • Arora, Aakriti, Emory University, Atlanta, Georgia, United States
  • Mozee, Hilton, Emory University, Atlanta, Georgia, United States
  • Cobb, Jason, Emory University, Atlanta, Georgia, United States
Background

Clinically significant kidney disease is estimated to occur in nearly 60% of patients with systemic lupus erythematosus (SLE). A majority of these patients develop proliferative disease, however 10-15% develop a non-proliferative form of disease known as membranous lupus nephritis (LN) (Class V lupus nephritis). These patients typically present with significant proteinuria. Austin et al. reported 7% of patients with low complements levels and 21% with elevated anti-dsDNA levels. In this study we assess serological activity (C3, C4, anti-dsDNA) of pure membranous LN in a predominantly black patient population

Methods

Kidney biopsy log from 2010 – 2017, and a retrospective chart review was completed. We excluded any patients with proliferative disease (active or chronic). We analyzed serological activity (C3 level, C4 level & anti-dsDNA) at time of renal biopsy and again at 24 weeks.

Results

Of the total 101 patients with pure membranous LN, we had 54 patients with sufficient follow-up data. 52 of the 54 patients were female with an average age of 35.5; 92.5% (50 of 54) were black. At time of kidney biopsy, low C3 and low C4 was found in 54% and 41% of patients respectively. Whereas an elevated anti-dsDNA was identified in 39% with 20% having the classic triad of low C3, low C4 and elevated anti-dsDNA. When compared to 24 weeks (roughly end of induction therapy) low C3 and low C4 was found in 37% and 24% of patients respectively. Whereas an elevated anti-dsDNA was identified in 31% with 13% have the combination of low C3, low C4 and elevated anti-dsDNA

Conclusion

In this predominantly black population of pure membranous LN the majority of patients did not have the classic triad of low complements and elevated dsDNA (20% at time of diagnosis/biopsy). Compared to others looking at pure membranous we did find higher rates of low complements and elevated anti-dsDNA at time of diagnosis (54% with low C3 initially). Possibly due to our unique urban patient population which is >90 percent black; i.e. more severe SLE. Despite the majority of patients not having the classic triad of low C3, low C4, and elevated anti-dsDNA, clinical providers must be diligent in assessing the need for kidney biopsy in SLE and non-SLE patients as serological activity does not correlate with biopsy findings. Earlier treatment correlates with improved prognosis.